Loading
A phase 3 trial of HS-20093 in lung cancer, run by Hansoh BioMedical R&D Company, not yet recruiting.
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06526624 by Hansoh BioMedical R&D Company, with a registry enrolment figure of 406 participants, started 2024-09-30 and due to reach its primary completion in 2027-11-30. Interventions recorded: HS-20093. Conditions listed: Limited-stage Small-cell Lung Cancer. Primary outcome: Progression-free survival (PFS) According to RECIST v1.1 by Independent Review Committee (IRC); Overall survival (OS). Lung eligibility wording from the registry: "Patients with limited-stage SCLC who are deemed unsuitable for surgery or decline surgery". No results are recorded here; the registry entry is the source.
Shares HS-20093, Hansoh Pharmaceutical, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Hansoh Pharmaceutical, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.